
    
      The study consists of two parts: Part A and Part B. Part A was closed to enrollment under
      Amendment 6. As of Amendment 7, the endpoints for Part A and Part B have been combined to
      assess the safety and tolerability of miransertib in participants with PROS and PS. Previous
      efficacy and pharmacokinetic (PK) objectives and endpoints have been removed.
    
  